CABA
Cabaletta Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.48
+4.96%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -26.1%
- EBIT
- -23.8%
- EPS
- +42.3%
- Free cash flow
- -45.1%
- Operating cash flow
- -47.1%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +73.6%
- EPS
- +24.0%
Three-year CAGR
- Revenue
- —
- EBITDA
- -44.8%
- EBIT
- -37.6%
- Net income
- -44.9%
- EPS
- +29.9%
- Free cash flow
- -46.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026